非病毒性ARDS的糖皮质激素应用:推荐超前于证据
本文为叙述性综述,围绕2024年ARDS全球新定义纳入无创呼吸支持患者后带来的异质性,梳理糖皮质激素在非病毒性ARDS中的证据与局限。DEXA-ARDS试验显示大剂量地塞米松降低中重度ARDS病死率,重症社区获得性肺炎中氢化可的松方案亦显示获益,但最佳药物、剂量、时机与适用表型仍未明确。
要点
- 2024年ARDS新定义纳入无创呼吸支持患者,增加疾病严重度与治疗反应异质性。
- 指南推荐中重度ARDS使用糖皮质激素,但未明确最佳时机、剂量与患者选择。
- 非病毒性感染相关ARDS可能是糖皮质激素的特定获益人群,需按表型个体化用药。
核心结论
- 指南推荐中重度ARDS使用糖皮质激素,但推荐超前于证据,最佳药物、剂量与适用表型尚未明确。
- 在精准方法明确前,临床医生需在经验性获益与审慎克制之间平衡非病毒性ARDS的糖皮质激素使用。
研究设计与样本
- 本文为简明综述,汇总当前证据、关键局限与基于表型的实用策略,未报告系统检索范围与样本量。
主要发现
- DEXA-ARDS试验显示大剂量地塞米松降低中重度ARDS病死率,且不受病因影响。
- CAPE-COD与APROCCHSS试验中重症社区获得性肺炎的氢化可的松方案显示病死率获益。
- 近期网络meta分析提示低剂量甲泼尼龙可能降低ARDS病死率,但表型特异性疗效未明确。
关键数值与推荐
- 2024年ARDS全球重新定义将诊断标准扩大至接受无创呼吸支持的患者。
- 近期指南推荐中重度ARDS使用糖皮质激素,但未规定最佳时机、剂量与患者选择。
临床怎么用
- 对非病毒性、感染相关的中重度ARDS可考虑糖皮质激素,但需结合表型个体化决策。
- 应用时应权衡经验性获益与审慎克制,避免对所有ARDS亚型一概而论。
局限性
- DEXA-ARDS结果对较轻或未插管患者的可推广性尚不明确。
- 各ARDS亚型证据积累不均衡,表型特异性疗效定义不足。
- 指南推荐可能掩盖个体化治疗所需的细微差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pneumonia (Nathan). 2025 Oct 5;17(1):28. doi: 10.1186/s41479-025-00183-x. ABSTRACT The 2024 global redefinition of acute respiratory distress syndrome (ARDS) broadens diagnostic criteria to include patients on non-invasive respiratory support. While this inclusivity enhances early recognition, it also introduces heterogeneity in disease severity, inflammatory burden, and treatment responsiveness-complicating the use of corticosteroids. Although recent guidelines recommend corticosteroids for moderate-to-severe ARDS, they fall short of specifying optimal timing, dosing, and patient selection. The DEXA-ARDS trial showed that high-dose dexamethasone reduced mortality in moderate-to-severe ARDS regardless of etiology, but its generalizability to less severe or non-intubated patients remains unclear. Conversely, in severe community-acquired pneumonia (CAP), hydrocortisone regimens used in CAPE-COD and APROCCHSS trials demonstrated mortality benefits, suggesting a particular therapeutic niche for corticosteroids in non-viral, infection-associated ARDS. A recent network meta-analysis suggests that low-dose methylprednisolone may reduce ARDS mortality, though phenotype-specific efficacy is not well defined. Despite these encouraging signals, key questions persist: Which corticosteroid? At what dose? For which ARDS phenotype? As evidence accumulates unevenly across ARDS subtypes, guideline-endorsed recommendations may inadvertently mask the nuances required for individualized therapy. Until precision approaches are better defined, clinicians must balance empirical benefit with thoughtful restraint in applying corticosteroids to non-viral ARDS. This concise review summarizes current evidence, key limitations, and pragmatic phenotype-informed strategies for corticosteroid use in non-viral ARDS. PMID: 41046258 | PMC: PMC12497343 | DOI: 10.1186/s41479-025-00183-x
引用
- 指南共识 · 肺炎:Corticosteroids in non-viral acute respiratory distress syndrome (ARDS): recommendations outpace evidence - a concise review
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。